Overcoming Cancers Resistant to HER-2 Antibodies

Overcoming Cancers Resistant to HER-2 Antibodies

  • Benjamin Bonavida
Publisher:Academic PressISBN 13: 9780128167380ISBN 10: 0128167386

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart GOSnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹7,714Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books ₹120Audible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

Overcoming Cancers Resistant to HER-2 Antibodies is written by Benjamin Bonavida and published by Academic Press. It's available with International Standard Book Number or ISBN identification 0128167386 (ISBN 10) and 9780128167380 (ISBN 13).

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies. - Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance - Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment - Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field